Success Metrics

Clinical Success Rate
66.7%

Based on 6 completed trials

Completion Rate
67%(6/9)
Active Trials
0(0%)
Results Posted
50%(3 trials)
Terminated
3(23%)

Phase Distribution

Ph not_applicable
3
23%
Ph phase_3
1
8%
Ph phase_1
4
31%
Ph phase_2
5
38%

Phase Distribution

4

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
4(30.8%)
Phase 2Efficacy & side effects
5(38.5%)
Phase 3Large-scale testing
1(7.7%)
N/ANon-phased studies
3(23.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

6 of 12 finished

Non-Completion Rate

50.0%

6 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(6)
Terminated(6)
Other(1)

Detailed Status

Completed6
Terminated3
Withdrawn3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (30.8%)
Phase 25 (38.5%)
Phase 31 (7.7%)
N/A3 (23.1%)

Trials by Status

unknown18%
terminated323%
withdrawn323%
completed646%

Recent Activity

0 active trials
Showing 5 of 13
terminatednot_applicable

The Effect of Caphosol® on the Development of Esophagitis in (N)SCLC Patients Treated With Concurrent Chemo/Radiotherapy

NCT01809756
terminatedphase_3

Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy

NCT02539342
completedphase_2

Supersaturated Calcium Phosphate Oral Rinse (Caphosol®) For the Prevention of Oral Mucositis in Children Undergoing Chemotherapeutic Treatments

NCT02807337
completedphase_1

Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma

NCT01983969
terminatedphase_1

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

NCT02589145
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT01809756Not Applicable

The Effect of Caphosol® on the Development of Esophagitis in (N)SCLC Patients Treated With Concurrent Chemo/Radiotherapy

Terminated
NCT02539342Phase 3

Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy

Terminated
NCT02807337Phase 2

Supersaturated Calcium Phosphate Oral Rinse (Caphosol®) For the Prevention of Oral Mucositis in Children Undergoing Chemotherapeutic Treatments

Completed
NCT01983969Phase 1

Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma

Completed
NCT02589145Phase 1

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Terminated
NCT02961816Phase 2

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Withdrawn
NCT02701673Phase 1

Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma

Withdrawn
NCT01426295Phase 2

Pharmaco-economic Study of a New Medical Device Performed From the Perspective of the Hospital

Completed
NCT01046812Not Applicable

Halitosis Devised Questionnaire Evaluating a New Treatment

Completed
NCT01758562Not Applicable

Caphosol® Versus State-of-the-art Mouthcare in Patients With Allogeneic Stem Cell Transplantation: a Randomized Controlled Study About the Efficacy of the Mouth Rinse Caphosol®

Completed
NCT02114502Phase 2

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Withdrawn
NCT00965172Phase 2

Caphosol in Sarcoma Patients With Mucositis

Completed
NCT00901732Phase 1

Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer

Unknown

All 13 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
13